Mineralys Therapeutics, Inc. (MLYS)
25.86
-0.73
(-2.75%)
USD |
NASDAQ |
Sep 25, 16:00
25.88
+0.02
(+0.08%)
After-Hours: 19:59
Mineralys Therapeutics Enterprise Value : 1.721B for Sept. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 1.721B |
| September 24, 2026 | 1.785B |
| September 23, 2026 | 1.812B |
| September 22, 2026 | 2.034B |
| September 21, 2026 | 1.937B |
| September 18, 2026 | 1.912B |
| September 17, 2026 | 1.908B |
| September 16, 2026 | 1.869B |
| September 15, 2026 | 1.990B |
| September 14, 2026 | 1.994B |
| September 11, 2026 | 1.928B |
| September 10, 2026 | 2.025B |
| September 09, 2026 | 2.131B |
| September 08, 2026 | 2.186B |
| September 04, 2026 | 1.929B |
| September 03, 2026 | 1.934B |
| September 02, 2026 | 2.002B |
| September 01, 2026 | 1.695B |
| August 31, 2026 | 1.704B |
| August 28, 2026 | 1.698B |
| August 27, 2026 | 1.734B |
| August 26, 2026 | 1.724B |
| August 25, 2026 | 1.763B |
| August 24, 2026 | 1.669B |
| August 21, 2026 | 1.702B |
| Date | Value |
|---|---|
| August 20, 2026 | 1.711B |
| August 19, 2026 | 1.817B |
| August 18, 2026 | 1.787B |
| August 17, 2026 | 1.738B |
| August 14, 2026 | 1.702B |
| August 13, 2026 | 1.741B |
| August 12, 2026 | 1.826B |
| August 11, 2026 | 1.851B |
| August 10, 2026 | 1.855B |
| August 07, 2026 | 1.853B |
| August 06, 2026 | 1.821B |
| August 05, 2026 | 1.808B |
| August 04, 2026 | 1.778B |
| August 03, 2026 | 1.714B |
| July 31, 2026 | 1.691B |
| July 30, 2026 | 1.750B |
| July 29, 2026 | 1.764B |
| July 28, 2026 | 1.817B |
| July 27, 2026 | 1.840B |
| July 24, 2026 | 1.796B |
| July 23, 2026 | 1.822B |
| July 22, 2026 | 1.823B |
| July 21, 2026 | 1.868B |
| July 20, 2026 | 1.796B |
| July 17, 2026 | 1.830B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 9.078B |
| Oncolytics Biotech, Inc. | 81.50M |
| Sangamo Therapeutics, Inc. | 51.40M |
| Sarepta Therapeutics, Inc. | 2.229B |
| Anixa Biosciences, Inc. | 81.18M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -241.07M |
| Total Expenses (Quarterly) | 241.07M |
| EPS Diluted (Quarterly) | -2.845 |
| Earnings Yield | -16.41% |
| Normalized Earnings Yield | -16.41 |